SCHEMBL22155229

SCHEMBL22155229

CCc1ccc(F)c(C#N)c1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 6/20 0.35
ALDH1A1 P00352 3/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 2/20 0.34
HPGD P15428 2/20 0.34
GFER P55789 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
CYP2A6 P11509 1/20 0.33
TRPV4 Q9HBA0 1/20 0.33
PKM P14618 1/20 0.33
GRIA2 P42262 2/20 0.33
GRIA4 P48058 2/20 0.33
KDM4E B2RXH2 2/20 0.32
HSD11B1 P28845 1/20 0.32
GLA P06280 1/20 0.31
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20283719 0.85 BCAT2 (0.34) CXCR2ALDH1A1POLBKMT2ALMNA
SCHEMBL20283904 0.82 ALDH1A1 (0.34) ALDH1A1POLBKMT2ALMNAHPGD
SCHEMBL20283896 0.81 S1PR1 (0.35) CXCR2ALDH1A1KMT2ALMNAHPGD
SCHEMBL29416940 0.80 CD274 (0.39) CXCR2ALDH1A1LMNAHPGDL3MBTL1
SCHEMBL20489910 0.80 CD274 (0.39) CXCR2ALDH1A1LMNAHPGDL3MBTL1
SCHEMBL24108090 0.80 MAPT (0.33) CXCR2ALDH1A1KMT2ALMNAHPGD
SCHEMBL4549080 0.79 CXCR2 (0.33) CXCR2ALDH1A1POLBKMT2ATRPV4
SCHEMBL9928613 0.78 MAPT (0.38) CXCR2ALDH1A1POLBKMT2ALMNA
SCHEMBL12648426 0.76 ALDH1A1 (0.44) CXCR2ALDH1A1POLBKMT2ALMNA
SCHEMBL186689 0.75 TRPV4 (0.42) ALDH1A1KMT2AHPGDTRPV4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10987359-B2 Oxadiazepinone derivatives and methods of treating hepatitis B infections NOVIRA THERAPEUTICS, INC. (US) 2021-04-27 US disclosed
US-20200197408-A1 OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS NOVIRA THERAPEUTICS, INC. 2020-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987359-B2 Oxadiazepinone derivatives and methods of treating hepatitis B infections HCCS, SLC10A1, PYGL CXCR2 1456/4885ALDH1A1 554/4885POLB 189/4885
US-20200197408-A1 OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS HCCS, SLC10A1, PYGL CXCR2 1456/4885ALDH1A1 554/4885POLB 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.